In recent years, the much-discussed concept of “patient centricity” has been top-of-mind across all corners of the pharma industry. This is especially pertinent now that many innovative drug makers are seeking to become much…
Rendering CGT Genuinely Patient Centric
Patient Engagement Roundtable: A Varied Global Picture
CAR-T and the Art of Managing Expectations
CGT, Real World Evidence & The Patient Experience
Long dismissed as the backwaters of healthcare innovation, the tremendous value of vaccines – the single most cost-effective health intervention after clean water – made itself starkly clear in 2020, as the discovery of a novel coronavirus quickly exploded into a full-blown global pandemic that rages on still. While billions have since been poured into vaccine development for COVID-19 and vaccine candidates have been developed and approved (albeit so far only for emergency use) at unprecedented speed, sector stakeholders are only…
R&D: An Expanded Playbook
Business Models and Market Access
Manufacturing and Supply Chain
Population Helath: Access & AntiVax Challenges
Once considered almost science fiction in medicine, personalised medicine is increasingly becoming a day-to-day reality for many patients. As innovative pharma continues to invest heavily in high-risk frontier research involving stem cells and the harnessing of a patient’s own immune system to attack…
Funding the Cell & Gene Therapy Boom
Reconsidering CGT Manufacturing
The Collaborative Spirit of Cell & Gene
RWE: Unlocking the full potential of Cell & Gene
The AI in Life Sciences Market was valued at USD 902.1 million in 2019 by Mordor Intelligence and is projected to expand at an impressive 20 percent compound annual growth rate in the period 2020 to 2024. Yet despite the massive hype and enthusiasm around artificial intelligence’s propensity…
De-risking Drug Discovery with Artifical Intelligence
Rethinking Healthcare Provision with AI
Challenges to AI in Life Sciences
Life Sciences’ Growing Demand for AI Assets
Cell and gene therapies are fast turning into a powerful engine of value creation for drugmakers and represent a paradigm shift in the treatment of some of the world’s most devastating and intractable illnesses. In the last five to ten years, for instance, we have witnessed innovative…
The Power of Cell & Gene
The Scalability and Manufacturing Barrier
Making CAR-T Therapy Affordable
Taking Cell & Gene Mainstream
European MidPharmas – R&D based pharmaceutical companies with annual revenues of between EUR 50 million and 5 billion – are having to be increasingly focused and resilient to succeed and fend off their inherent vulnerabilities according to a new report from specialist pharma…
European MidPharmas: Focused and Resilient, yet Vulnerable
Swiss Mid-Caps and Minnows: At the Vanguard of Creativity
Spanish Mid-Caps: Going Global
5 Top European Mid-Cap CEOs To Know
The reappearance of cannabis as a tool in our therapeutic toolbox comes at an important time when we have not witnessed any real advances in…
Canada’s Cannabis Pioneers Go Global
Company Profile: GW Pharmaceuticals
The Medical Cannabis Investment Landscape
The Cannabis Companies Behaving Like Biotechs
Long regarded as a neglected backwater within the drug discovery landscape and the preserve of only a handful of niche players, the rare disease space has been undergoing an extraordinary turnaround in fortunes of late…
5 Key Trends in Orphan Drugs & Rare Diseases
Rare Disease Company Acquisitions Continue Apace
Why Invest in Rare Diseases & Orphan Drugs?
Rethinking Clinical Trials in Rare Diseases
Contact us
+44 20 7867 3717 info@gamma.pharma.kalyna.dev
For media inquiries, please contact: media@gamma.pharma.kalyna.dev
Address
PharmaBoardroom Limited Lynton House, 7-12, Tavistock Square, London, United Kingdom, WC1H 9LT